SCHEDULE Filed 2025-03-07 Event 2025-03-05 SEC 0001140361-25-007701 →

KKR Genetic Disorder L.P. → BridgeBio Pharma, Inc. BBIO

Stake: 10.10% Shares: 19,260,971 CUSIP: 10806X102 Class: Common Stock, par value $0.001 per share

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 37/100 · Filer 90d Win Rate: 100% · Hist. 90d Edge: +21.3%

Passive Schedule 13G filer baseline
High conviction ownership stake (10.1%)
Held by 2 tracked 13F institutional managers
19 NPORT-P mutual funds holding CUSIP
Elevated short days-to-cover (7.7 DTC)

Item 4 — Purpose of Transaction

Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The information set forth in Item 5(c) below is incorporated by reference herein.

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

11 13D/G filings on this issuer

10 other filings besides this one

Filer Track Record

4 filings by this filer

3 other filings in the data moat

Short Interest · settle 2026-10-15

DTC 7.68

19,997,556 shares short · +1.7% vs prior

Institutional Consensus · 2026-06-30

Held by elite portfolio managers

2 holders · $741.60M

Point72 Asset MgmtViking Global

Post-Filing Returns · since 2025-03-05 on BBIO

+1 day

-7.8%

+5 days

-10.2%

+30 days

-10.3%

+60 days

+9.3%

+90 days

+7.3%

+180 days

+43.0%

Anchor price 34.97 on closest trading day on/after 2025-03-05. Source: Yahoo Finance daily adj_close (split + dividend adjusted).

Other 13D/G Filings on BridgeBio Pharma, Inc.

Filed	Form	Filer	Stake	Shares
2026-08-17	SCHEDULE 13D/A	KKR Genetic Disorder L.P.	—	8,260,971	view →
2026-07-10	SCHEDULE 13D/A	VIKING GLOBAL INVESTORS LP	5.00%	9,792,219	view →
2026-05-29	SCHEDULE 13G	Farallon Capital Partners, L.P.	—	—	view →
2026-04-02	SCHEDULE 13D/A	VIKING GLOBAL INVESTORS LP	6.10%	11,842,434	view →
2025-07-01	SCHEDULE	VIKING GLOBAL INVESTORS LP	9.80%	18,602,920	view →
2025-05-14	SCHEDULE	KKR Genetic Disorder L.P.	7.00%	13,260,971	view →
2025-01-31	SCHEDULE	VIKING GLOBAL INVESTORS LP	11.70%	22,055,375	view →
2023-07-20	SC	VIKING GLOBAL INVESTORS LP	—	—	view →
2021-01-26	SC	Eidos Therapeutics, Inc.	—	—	view →
2020-06-01	SC	KKR Genetic Disorder L.P.	—	—	view →

Other Filings by KKR Genetic Disorder L.P.

Filed	Form	Issuer	Stake	Shares
2026-08-17	SCHEDULE 13D/A	BridgeBio Pharma, Inc.	—	8,260,971	view →
2025-05-14	SCHEDULE	BridgeBio Pharma, Inc. BBIO	7.00%	13,260,971	view →
2020-06-01	SC	BridgeBio Pharma, Inc. BBIO	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →